Immucell Stock Buy Hold or Sell Recommendation
| ICCC Stock | USD 3.69 0.03 0.82% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding ImmuCell is 'Strong Sell'. Macroaxis provides ImmuCell buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ImmuCell positions.
Check out ImmuCell Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide. In addition, we conduct extensive research on individual companies such as ImmuCell and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
ImmuCell |
Execute ImmuCell Buy or Sell Advice
The ImmuCell recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ImmuCell. Macroaxis does not own or have any residual interests in ImmuCell or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ImmuCell's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
ImmuCell Trading Alerts and Improvement Suggestions
| The company reported the previous year's revenue of 17.47 M. Net Loss for the year was (5.77 M) with profit before overhead, payroll, taxes, and interest of 7.65 B. | |
| ImmuCell currently holds about 11.04 M in cash with (4.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.43. | |
| ImmuCell has a frail financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ImmuCell Q3 Earnings Decline YY, Sales Grow Amid Margin Challenges - MSN |
ImmuCell Returns Distribution Density
The distribution of ImmuCell's historical returns is an attempt to chart the uncertainty of ImmuCell's future price movements. The chart of the probability distribution of ImmuCell daily returns describes the distribution of returns around its average expected value. We use ImmuCell price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ImmuCell returns is essential to provide solid investment advice for ImmuCell.
| Mean Return | 0.07 | Value At Risk | -3.29 | Potential Upside | 3.40 | Standard Deviation | 2.68 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ImmuCell historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ImmuCell Stock Institutional Investors
| Shares | Hightower Advisors, Llc | 2024-06-30 | 21.4 K | Susquehanna International Group, Llp | 2024-06-30 | 20.8 K | Prosperity Planning, Inc. | 2024-09-30 | 16 K | Blackrock Inc | 2024-06-30 | 13.8 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-09-30 | 12.2 K | Essex Financial Services, Inc. | 2024-06-30 | 11 K | Hm Payson & Co | 2024-09-30 | 4 K | Ubs Group Ag | 2024-06-30 | 2.7 K | Bank Of America Corp | 2024-06-30 | 2.1 K | Vanguard Group Inc | 2024-09-30 | 225.6 K | Cresset Asset Management, Llc | 2024-06-30 | 207.2 K |
ImmuCell Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (186.6K) | 425.7K | (997.5K) | (2.9M) | (1.8M) | (1.7M) | |
| Free Cash Flow | (1.2M) | (2.8M) | (1.7M) | (5.5M) | (6.6M) | (6.2M) | |
| Depreciation | 2.3M | 2.3M | 2.5M | 2.5M | 2.7M | 2.9M | |
| Other Non Cash Items | 19.4K | (780.4K) | 18.6K | 28.8K | 260.8K | 273.9K | |
| Capital Expenditures | 1.4M | 4.1M | 2.6M | 4.0M | 1.9M | 1.6M | |
| Net Income | (1.3M) | (1.0M) | (78.3K) | (2.5M) | (5.8M) | (5.5M) | |
| End Period Cash Flow | 6.3M | 6.9M | 10.2M | 5.8M | 978.7K | 929.8K | |
| Change In Cash | 3.8M | 656.6K | 3.2M | (4.4M) | (4.8M) | (4.6M) | |
| Investments | (2.0M) | (2.6M) | (1.6M) | (4.0M) | (3.4M) | (3.2M) | |
| Change Receivables | (306.3K) | 411.7K | (732.6K) | (132.4K) | (119.1K) | (125.1K) | |
| Net Borrowings | (1.4M) | 2.0M | (368.3K) | 1.1B | 1.3B | 1.3B | |
| Change To Netincome | 357.3K | (644.6K) | 186.0K | 287.4M | 330.5M | 347.0M |
ImmuCell Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ImmuCell or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ImmuCell's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ImmuCell stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | -0.66 | |
σ | Overall volatility | 2.70 | |
Ir | Information ratio | -0.02 |
ImmuCell Volatility Alert
ImmuCell currently demonstrates below-average downside deviation. It has Information Ratio of -0.02 and Jensen Alpha of 0.14. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ImmuCell's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ImmuCell's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.ImmuCell Fundamentals Vs Peers
Comparing ImmuCell's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ImmuCell's direct or indirect competition across all of the common fundamentals between ImmuCell and the related equities. This way, we can detect undervalued stocks with similar characteristics as ImmuCell or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ImmuCell's fundamental indicators could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ImmuCell to competition |
| Fundamentals | ImmuCell | Peer Average |
| Return On Equity | -0.16 | -0.31 |
| Return On Asset | -0.0487 | -0.14 |
| Profit Margin | (0.17) % | (1.27) % |
| Operating Margin | (0.25) % | (5.51) % |
| Current Valuation | 44.61 M | 16.62 B |
| Shares Outstanding | 8.91 M | 571.82 M |
| Shares Owned By Insiders | 39.52 % | 10.09 % |
| Shares Owned By Institutions | 14.51 % | 39.21 % |
| Number Of Shares Shorted | 4.01 K | 4.71 M |
| Price To Earning | 195.00 X | 28.72 X |
| Price To Book | 1.25 X | 9.51 X |
| Price To Sales | 1.42 X | 11.42 X |
| Revenue | 17.47 M | 9.43 B |
| Gross Profit | 7.65 B | 27.38 B |
| EBITDA | (2.5 M) | 3.9 B |
| Net Income | (5.77 M) | 570.98 M |
| Cash And Equivalents | 11.04 M | 2.7 B |
| Cash Per Share | 1.43 X | 5.01 X |
| Total Debt | 16.69 M | 5.32 B |
| Debt To Equity | 0.36 % | 48.70 % |
| Current Ratio | 6.91 X | 2.16 X |
| Book Value Per Share | 3.23 X | 1.93 K |
| Cash Flow From Operations | (4.67 M) | 971.22 M |
| Short Ratio | 0.23 X | 4.00 X |
| Earnings Per Share | (0.49) X | 3.12 X |
| Target Price | 14.0 | |
| Number Of Employees | 75 | 18.84 K |
| Beta | 0.57 | -0.15 |
| Market Capitalization | 32.08 M | 19.03 B |
| Total Asset | 43.81 M | 29.47 B |
| Retained Earnings | (12.01 M) | 9.33 B |
| Working Capital | 10.92 M | 1.48 B |
| Current Asset | 4.49 M | 9.34 B |
Note: Acquisition by Tomsche David Scott of 606 shares of ImmuCell at 7.75 subject to Rule 16b-3 [view details]
ImmuCell Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ImmuCell . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About ImmuCell Buy or Sell Advice
When is the right time to buy or sell ImmuCell? Buying financial instruments such as ImmuCell Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having ImmuCell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency Thematic Idea Now
Cryptocurrency
Dynamically computed list of top cryptocurrencies sorted bymarket capitalization. The Cryptocurrency theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ImmuCell Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.